Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 1 Study of NKX019, a CD19 Chimeric Antigen Receptor Natural Killer (CAR NK) Cell Therapy, in Subjects With Systemic Lupus Erythematosus

Next Previous
Trial Profile

A Phase 1 Study of NKX019, a CD19 Chimeric Antigen Receptor Natural Killer (CAR NK) Cell Therapy, in Subjects With Systemic Lupus Erythematosus

Status: Recruiting
Phase of Trial: Phase I

Latest Information Update: 27 Jul 2025

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Cyclophosphamide (Primary) ; NKX 019 (Primary)
  • Indications Lupus nephritis; Systemic lupus erythematosus
  • Focus Adverse reactions

Most Recent Events

  • 14 May 2025 According to a Nkarta Therapeutics media release, the trial is being led by Anca D. Askanase, M.D, M.P.H, Director, Lupus Center at Columbia University Irving Medical Center and the Director of Rheumatology Clinical Trials.
  • 07 Nov 2024 According to a Nkarta Therapeutics media release, first patient has been dosed at at Columbia University Irving Medical Center (CUIMC). Trial was initiated in July 2024.
  • 29 Jul 2024 New trial record

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top